iCAD Announces Proposed Public Offering of Common Stock

World News: . []

NASHUA, N.H., June 12, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it has commenced an underwritten registered public offering of its common stock.  In addition, iCAD intends to grant the underwriter a 30-day option to purchase additional shares, in a number equal to up to 15% of the number of shares of common stock sold in the offering, to cover over-allotments, if any.  All shares of common stock to be sold in the proposed offering will be offered by iCAD.   The proposed offering is subject to market and other conditions, as well as customary closing conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering.

iCAD intends to use the net proceeds of the proposed offering for working capital and other general corporate purposes.

Craig-Hallum Capital Group is acting as sole managing underwriter for the proposed offering.

A registration statement on Form S-3 (File No. 333-228514) relating to the shares of common stock of iCAD to be sold in the proposed offering was declared effective by the Securities and Exchange Commission (the "SEC") on December 4, 2018. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering have been filed with the SEC and may be obtained by visiting EDGAR on the SEC's website at www.sec.gov or by contacting Craig-Hallum Capital Group LLC at 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, Attention Equity Capital Markets, by telephone at 612-334-6300, or by email at prospectus@chlm.com. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

Investor Relations: LifeSci Advisors, on behalf of iCAD, Inc. Jeremy Feffer, (212) 915-2568 jeremy@lifesciadvisors.com

iCAD, Inc. 603.882.5200 pr@icadmed.com

More news and information about iCAD, Inc.

Published By:

Globe Newswire: 21:16 GMT Wednesday 12th June 2019

Published: .

Search for other references to "icad" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us